Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield 0.1% (LTM)
  • Share price is 48.1% higher than minimum and 18.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (11.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.3 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-1.9%)108.83
year average price 87.71  


year start price 97.92 2025-01-19

min close price 73.47 2025-05-14

max close price 111.01 2026-01-14

current price 108.83 2026-01-18
Common stocks: 2 528 810 012

Dividend Yield:  3.0%
FCF Yield LTM: 0.1%
EV / LTM EBITDA: 11.3x
EV / EBITDA annualized: 9.4x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 275 210
Net Debt ($m): 23 217
EV (Enterprise Value): 298 427
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 11.3x
Price to Book: 5.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-15zacks.com

Why Merck's 32% Rally Isn't Enough to Change the Bearish View

2026-01-15forbes.com

Is Merck Stock A Trap At $110?

2026-01-14zacks.com

Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?

2026-01-12seekingalpha.com

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12reuters.com

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

2026-01-02zacks.com

Merck (MRK) Laps the Stock Market: Here's Why

2026-01-01seekingalpha.com

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

2026-01-01seekingalpha.com

Merck: Framework For Success

2025-12-30seekingalpha.com

Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

2025-12-30zacks.com

Why Merck (MRK) is a Top Value Stock for the Long-Term
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data